In a challenging macroeconomic climate, we prefer Argan and confirm our Outperform rating on the stock with a target price of € 120 (total return of +30%) We see it benefiting from solid fundamentals in the logistics segment and gaining visibility. - ...
Dans un environnement macro difficile, nous privilégions Argan et réitérons notre recommandation Surperformance sur le titre avec un OC à 120 € (total return +30%). Nous la voyons bénéficier des bons fondamentaux de la filière logistique et gagner en visibilité. - ...
>96.9% tendered after end of post acceptance period - Accell has issued a press release in which it states that during the post acceptance period (which ended yesterday), 5.7m shares were tendered while the consortium also bought 24k shares in the market yesterday. As a result, the consortium now holds 96.9% of the outstanding shares of Accell meaning that, after settlement, normal squeeze out procedures can be executed enabling the consortium to gain 100% of the outs...
>Deal highly likely to succeed - Yesterday evening, KKR and Teslin announced that they have received irrevocable commitments of shareholders representing 4.26% of the outstanding shares. As a result, the total percentage of shares tendered/committed now stands at 77.8%. In addition, KKR and Teslin have also been able to convince the Accell boards that sufficient shares will be tendered in the post acceptance period by passive and other investors (7-9% was our initial ...
>Extension of tender period most likely next step - The outcome of the June 3rd tender offer was a disappointment for the consortium of KKR/Teslin as 73.53% of the outstanding shares were tendered, which is below the required 80.01%. KKR/Teslin now have until June 9 to determine what they are going to do next. There are multiple scenarios but the most likely one in our view is that KKR/Teslin will extend the acceptance period by at least two weeks (max 10 weeks) and s...
We held our twenty-seventh ABN AMRO – ODDO BHF Benelux Forum this week. For the first time in three years the conference was in physical mode at the headquarters of ABN AMRO, which was well appreciated by investors and issuers. This year some 66 institutional investors had a total of 140 meetings with 21 issuers. We welcomed investors from the Netherlands, Belgium, Germany, France, Switzerland and the UK - ...
We held our twenty-seventh ABN AMRO – ODDO BHF Benelux Forum this week. For the first time in three years the conference was in physical mode at the headquarters of ABN AMRO, which was well appreciated by investors and issuers. This year some 66 institutional investors had a total of 140 meetings with 21 issuers. We welcomed investors from the Netherlands, Belgium, Germany, France, Switzerland and the UK - ...
>All resolutions adopted at EGM, including triangular merger resolution - At the EGM last Friday, all proposed resolutions were adopted. This included the conditional appointment of the new supervisory board members of Accell (2 KKR partners and 1 Teslin representative), the amendments of the articles of association, the discharge of the supervisory board and management board and resolution 2b, the post-settlement restructuring solution, which is effectively the trian...
>Attendance and voting at EGM critical, especially in relation to the triangular merger resolution - Although slim, there is still a chance that investors can ‘force’ KKR/Teslin to raise their offer for Accell as investors can block the adoption of the triangular merger, possibly resulting in Accell remaining listed, a highly undesirable outcome for KKR/Teslin. The articles of association of Accell state that all resolutions at the general meeting are adopted by...
We are maintaining our Neutral recommendation on the stock after factoring the integration of Photosol into our model. The group now benefits from a structural green growth driver it needs to accelerate through synergies and acquisitions to justify the price paid. - - ...
Recommandation Neutre réitérée sur la valeur post intégration de Photosol dans notre modèle. Le groupe dispose dorénavant d’un relais structurel de croissance verte qu’il doit accélérer par des synergies et des acquisitions pour justifier le prix payé. - - ...
>Facts: Solid set of results in 2H21 - Accell reported sales of €678m, beating consensus by 1% with underlying EBIT coming in at €45.5m, a beat of 4%. The underlying EBIT margin was 6.7%, 20bp better than consensus. Net profit was a clear miss due to a €10m incidental item in financial expenses and much higher than expected taxes. NWC as a % of sales came in at 33% versus our expectation of 295% (up from 17% at 1H21) and because of that higher NWC, FCF came in at €127...
On the back of decreasing headwind from the coronavirus pandemic and improving underlying trends (Medicare Advantage, FME25 and positive contributions from value-based care), we expect earnings to move upwards again (FY 2023e adj. EBIT growth of 21%). Increasing positive newsflow and improving top- and bottom-line momentum make Fresenius Medical Care attractive again in our view. We upgrade to Outperform with a new peer group/DCF-derived target price of € 72. - ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.